Jurors rejected an Arizona man’s claim that AbbVie Inc.’s AndroGel testosterone booster caused blood clots two months after he started taking the product, in the company’s first federal-court win in the litigation.
On Jan. 26 in Chicago, jurors rebuffed Robert Nolte’s arguments that the testosterone-replacement medicine caused a 2012 blood clot in the retired computer consultant’s throat that forced him into the hospital. It’s the company’s first trial win in the consolidated federal cases after two losses.
AbbVie has suffered as revenue from AndroGel, once a top-seller, slid after regulators called for tougher warning labels. The company faces more than ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.